EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sodium-glucose cotransporter 2 inhibitor use and outcomes after surgical aortic valve replacement

Xander Jacquemyn, Irsa Hasan, Takuya Ogami, Derek Serna-Gallegos, Johannes Bonatti, Mohamed Abdullah, Danny Chu, David J Kaczorowski, Ibrahim Sultan

The Journal of Thoracic and Cardiovascular Surgery · 2026

DOI: 10.1016/j.jtcvs.2026.02.037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2026. Verfasst von Xander Jacquemyn und 8 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pa; Department of Cardiothoracic Surgery, University of Pitts…. Hauptthemen laut MEDLINE: Heart Valve Prosthesis Implantation, Sodium-Glucose Transporter 2 Inhibitors, Aortic Valve Stenosis, Aortic Valve. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Sodium-glucose cotransporter 2 inhibitors have demonstrated mortality and heart failure hospitalization benefits across cardiovascular populations. However, their impact on patients with severe aortic stenosis undergoing surgical aortic valve replacement, with or without concomitant coronary artery bypass grafting, remains unclear. This study evaluated clinical outcomes associated with sodium-glucose cotransporter 2 inhibitor use in a real-world surgical aortic valve replacement population. METHODS: Patients who underwent surgical aortic valve replacement or combined surgical aortic valve replacement and coronary artery bypass grafting between 2014 and 2025 were reviewed. The inclusion criteria were consistent with contemporary trials including severe aortic valve replacement with left ventricular ejection fraction 40% or less, estimated glomerular filtration rate 25 to 75 mL/min/1.73 m2, or type 2 diabetes mellitus. Propensity score matching was used to adjust for baseline differences. The primary outcome was all-cause mortality. Secondary outcomes included stroke, heart failure hospitalization, atrial fibrillation admission, and all-cause rehospitalization. RESULTS: A total of 2930 patients (age 76 [69-83] years, 40.3% female) were included, of whom 85 (2.9%) received sodium-glucose cotransporter 2 inhibitor therapy. In the overall cohort, sodium-glucose cotransporter 2 inhibitor use was associated with significantly lower 5-year all-cause mortality compared with nonuse (13.6% vs 33.5%, log-rank P = .022). After matching, mortality remained lower among sodium-glucose cotransporter 2 inhibitor users (13.8% vs 25.8%, P = .012), with reduced stroke incidence (2.0% vs 19.3%; P = .046) and no significant differences in atrial fibrillation or rehospitalization. CONCLUSIONS: In patients undergoing surgical aortic valve replacement, perioperative sodium-glucose cotransporter 2 inhibitor therapy was associated with improved 5-year survival and reduced stroke risk. These observational findings are hypothesis generating and support further investigation of sodium-glucose cotransporter 2 inhibitors in prospective, randomized studies in the surgical valve population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve Prosthesis ImplantationSodium-Glucose Transporter 2 InhibitorsAortic Valve StenosisAortic ValveHumansFemaleAged, 80 and overAgedMaleTreatment OutcomeRetrospective StudiesRisk FactorsPatient ReadmissionTime FactorsCoronary Artery Bypass

Stichwörter der Autor:innen

SGLT2 inhibitoraortic stenosisaortic valve replacementsodium-glucose cotransporter 2 inhibitorsurgical aortic valve replacement

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • UPMC Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pa; Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pa.
  • UPMC Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pa; Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pa. Electronic address: sultani@upmc.edu.

Zitieren

APA

Jacquemyn, X., Hasan, I., Ogami, T., Serna-Gallegos, D., Bonatti, J., Abdullah, M., Chu, D., Kaczorowski, D. J., & Sultan, I. (2026). Sodium-glucose cotransporter 2 inhibitor use and outcomes after surgical aortic valve replacement. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2026.02.037

Vancouver

Jacquemyn X, Hasan I, Ogami T, Serna-Gallegos D, Bonatti J, Abdullah M, et al. Sodium-glucose cotransporter 2 inhibitor use and outcomes after surgical aortic valve replacement. The Journal of Thoracic and Cardiovascular Surgery. 2026. doi:10.1016/j.jtcvs.2026.02.037

BibTeX
@article{Jacquemyn2026,
  author = {Jacquemyn, Xander and Hasan, Irsa and Ogami, Takuya and Serna-Gallegos, Derek and Bonatti, Johannes and Abdullah, Mohamed and Chu, Danny and Kaczorowski, David J and Sultan, Ibrahim},
  title = {Sodium-glucose cotransporter 2 inhibitor use and outcomes after surgical aortic valve replacement},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2026},
  doi = {10.1016/j.jtcvs.2026.02.037}
}
Kostenlos starten →